ERIS Lifesciences Ltd logo

ERIS Lifesciences Ltd

ERIS NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹18,551 Cr
Volatility
Moderate
P/E Ratio
28.88
EBITDA
₹1,088 Cr
Return on Equity
11.45%
Debt to Equity
0.6
Book Value
₹281.61
EPS
₹27.95
52W High
₹1,820
52W Low
₹1,200

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view ERIS Lifesciences Ltd insights

48 extracted metrics + investor summaries across FY11–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Weaknesses

2
  • Stock is trading at 4.79 times its book value
  • Tax rate seems low

Growth Rate

Revenue Growth
6.97% ↘
Net Income Growth
28.40% ↗
Cash Flow Change
119.13% ↗
ROE
-7.06% ↗
ROCE
11.27% ↗
EBITDA Margin (Avg.)
-2.00% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Eris Lifesciences is a chronic-therapy-focused Indian pharma company trading at a market cap of ₹18,743 crore and a P/E of 28.1x. FY25 consolidated revenue grew 44% YoY to ₹2,894 crore with EBITDA expanding 51% to ₹1,017 crore, though FY26 revenue growth moderated to 8% at ₹3,129 crore. The stock has declined 19% over the past year despite strong operating fundamentals in prior periods.

Bull Case 8
  • FY25 revenue grew 44% YoY to ₹2,894 crore, demonstrating strong top-line scaling after the Biocon Biologics domestic formulations acquisition
  • FY25 EBITDA surged 51% YoY to ₹1,017 crore with margin expanding to approximately 35-36%, indicating operating leverage
  • 85% of portfolio is in chronic and sub-chronic therapies, providing high prescription stickiness and recurring revenue visibility
  • Compounded sales CAGR of 23% over 3 years and 21% over 5 years reflects consistent above-market growth
  • Return on equity has been steady at 16-19% over the past 3-5 years, indicating consistent capital efficiency
  • Insulin market share increased from 12% to 16%, showing share gains in a large addressable category
  • FY26 EBITDA margin expanded to 37% with 10% EBITDA growth even as revenue growth moderated, showing cost discipline
  • Compounded profit CAGR of 69% on a TTM basis reflects strong earnings recovery trajectory
Bear Case 8
  • FY26 revenue growth decelerated sharply to 8% from 44% in FY25, raising questions about organic growth momentum post-acquisition
  • Stock is trading at 4.80x book value, which is elevated for a pharma company with a debt-to-equity ratio of approximately 0.60
  • Stock price has declined 19% over the past 1 year despite the broader market rally, signalling investor concern
  • P/E of 28.1x is a premium valuation that leaves limited margin of safety if growth continues to moderate
  • Debt-to-equity ratio stands at approximately 0.60 following acquisitions, up from 0.40 in FY22, increasing financial risk
  • Tax rate appears low, which if normalised upward could compress reported net profit margins
  • Dividend yield of only 0.53% offers minimal income support during periods of capital depreciation
  • PAT for FY25 was ₹375 crore — only 6% growth over FY24's ₹397 crore — suggesting profit growth lagged revenue growth due to integration costs and higher interest

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 19h ago
Neutral 5
  • ₹64.40 Cr loan from Axis Bank Aug 6

    Eris Lifesciences drew down a ₹64.40 crore working capital term loan from Axis Bank to meet short-term liabilities. Aggregate debt level remains unchanged.

  • Q1FY27 earnings call transcript released Aug 4

    Eris released its Q1FY27 analyst and investor call transcript from the August 4, 2026 discussion. Full earnings details available on the company website.

  • Analyst meet with Tokio Marine Aug 12

    Eris will host a one-on-one virtual meeting with Tokio Marine Asset Management on August 17, 2026, per SEBI disclosure norms.

  • Analyst meet with Bandhan MF Jul 30

    Eris scheduled a virtual one-on-one meeting with Bandhan Mutual Fund on August 4, 2026, at 4:00 PM IST to discuss publicly available information.

  • Q1 FY27 earnings call scheduled Jul 23

    Eris announced an analyst call on July 29, 2026, to discuss Q1 FY27 results following the Board's review of unaudited financials.

TL;DR: A quiet period for Eris Lifesciences with no material positive or negative catalysts. The company drew a ₹64.40 Cr working capital loan without increasing aggregate debt, and routine analyst engagement with institutional investors like Tokio Marine and Bandhan MF signals continued institutional interest. The trend is steady with no visible deterioration or improvement from the news flow alone.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
467
505
486
551
720
741
727
705
773
792
807
757
873
Expenses
297
324
311
402
470
477
477
453
496
504
526
484
577
Operating Profit
170
181
176
148
250
265
250
252
277
288
282
272
296
OPM %
36%
36%
36%
27%
35%
36%
34%
36%
36%
36%
35%
36%
34%
Other Income
1
3
4
15
2
5
4
8
4
3
-17
2
2
Interest
17
16
18
33
60
59
57
54
49
50
49
46
47
Depreciation
41
42
46
54
76
80
81
77
71
69
70
70
72
PBT
112
126
116
77
116
129
116
129
161
173
145
159
179
Tax %
17%
3%
12%
-4%
22%
25%
25%
21%
22%
22%
25%
-75%
20%
Net Profit
94
122
101
80
90
96
87
102
125
134
109
279
143
EPS in Rs
6.98
9.07
7.55
5.22
6.12
6.73
6.15
6.89
8.66
8.82
7.32
20.33
10.28
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
546
597
750
856
982
1,074
1,212
1,347
1,685
2,009
2,894
3,129
3,230
Expenses
427
425
480
533
637
702
781
858
1,146
1,332
1,876
2,009
2,092
Operating Profit
118
172
269
322
345
372
431
489
539
677
1,018
1,120
1,138
OPM %
22%
29%
36%
38%
35%
35%
36%
36%
32%
34%
35%
36%
35%
Other Income
7
3
25
26
31
12
9
22
9
22
18
-9
-9
Interest
0
0
1
11
23
2
2
4
26
85
231
193
191
Depreciation
16
20
23
26
36
50
43
65
117
183
315
280
281
PBT
109
154
270
312
317
331
394
442
405
431
489
639
657
Tax %
18%
13%
9%
6%
8%
11%
10%
8%
8%
8%
23%
-1%
—
Net Profit
89
135
247
295
291
297
355
406
374
397
375
648
666
EPS in Rs
6,489
9,714
17.95
21.39
21.15
21.84
26.16
29.88
28.1
28.82
25.84
44.72
46.75
Div. Payout %
0%
63%
0%
0%
0%
13%
21%
20%
26%
0%
28%
16%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.14
0.14
14
14
14
14
14
14
14
14
14
14
Reserves
266
299
553
848
1,137
1,283
1,563
1,895
2,182
2,573
2,841
3,889
Borrowings
1
0
1
377
176
0
7
84
877
2,781
2,478
2,359
Other Liabilities
91
98
124
170
175
205
202
233
337
1,366
1,412
1,104
Total Liabilities
357
397
692
1,408
1,502
1,502
1,785
2,226
3,410
6,734
6,744
7,366
Fixed Assets
72
71
232
771
761
875
854
918
2,568
4,319
5,306
5,188
CWIP
0
0
0
0
3
4
2
27
22
20
67
171
Investments
167
190
303
365
356
78
294
520
37
16
67
62
Other Assets
119
136
157
271
383
544
636
761
783
2,379
1,304
1,945
Total Assets
357
397
692
1,408
1,502
1,502
1,785
2,226
3,410
6,734
6,744
7,366
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
90
131
200
235
223
271
375
378
292
486
1,065
538
Investing
-92
-44
-184
-590
-5
123
-323
-320
-975
-1,828
-78
-369
Financing
0
-84
-24
363
-221
-335
-82
-45
688
1,380
-881
-314
Net Cash Flow
-2
4
-8
8
-3
60
-30
14
5
38
105
-145
Free Cash Flow
77
108
150
210
186
125
350
258
-550
357
910
241
CFO/OP
96
97
94
94
85
87
103
94
68
87
114
59
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
16
16
24
28
31
53
42
44
63
77
58
79
Inventory Days
223
178
195
178
196
148
145
166
136
182
171
200
Days Payable
142
92
134
247
200
213
157
166
129
210
170
151
Cash Conversion Cycle
97
102
84
-40
28
-12
30
44
70
48
59
129
Working Capital Days
15
9
23
-13
-17
59
64
75
50
-296
-49
-71
ROCE %
47%
53%
60%
34%
26%
25%
27%
25%
17%
11%
12%
14%

Shareholding Pattern

As of Jun 2026
Promoters 54.14%
DIIs 20.72%
Public 10.10%
Others 9.29%
FIIs 5.75%
Total 100.00%
  Jan 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
55.55%
54.13%
52.69%
52.68%
52.66%
52.66%
52.30%
52.29%
52.70%
52.86%
52.86%
54.91%
54.90%
54.90%
54.88%
54.87%
54.86%
54.85%
54.83%
54.85%
54.85%
53.92%
54.14%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
13.20%
0.00%
14.27%
14.59%
8.01%
8.35%
8.43%
8.40%
7.21%
6.85%
6.39%
5.75%
DIIs
10.52%
9.25%
9.66%
9.57%
9.99%
10.11%
10.36%
10.38%
9.94%
10.02%
10.28%
14.53%
13.86%
15.63%
16.23%
18.64%
18.06%
18.07%
18.17%
19.36%
20.32%
20.35%
20.72%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
22.42%
23.28%
23.23%
23.29%
23.19%
23.14%
21.34%
21.27%
21.45%
21.66%
22.07%
15.47%
15.67%
14.24%
13.53%
10.51%
9.29%
9.16%
9.12%
9.12%
8.51%
10.06%
10.10%
Others
11.51%
13.34%
14.42%
14.46%
14.16%
14.09%
16.01%
16.07%
15.90%
15.46%
14.79%
1.90%
15.57%
0.95%
0.77%
7.96%
9.43%
9.49%
9.47%
9.45%
9.48%
9.26%
9.29%
No. of Shareholders
29,195
41,470
46,477
49,833
54,223
57,061
51,639
48,055
46,746
45,931
44,169
42,245
46,496
51,753
44,176
46,346
53,314
50,087
52,225
59,438
54,713
51,656
50,798

Documents

Frequently Asked Questions about ERIS Lifesciences Ltd

What does ERIS Lifesciences Ltd do?
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]
Where is ERIS Lifesciences Ltd (ERIS) listed?
ERIS Lifesciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: ERIS and BSE: 540596. You can view its live share price, financials, and ratios on Tapetide.
Which sector does ERIS Lifesciences Ltd belong to?
ERIS Lifesciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd has a market capitalisation of approximately ₹18551.38 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of ERIS Lifesciences Ltd?
The Price-to-Earnings (PE) ratio of ERIS Lifesciences Ltd is 28.88. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of ERIS Lifesciences Ltd?
Over the past 52 weeks, ERIS Lifesciences Ltd has traded between a low of ₹1,200 and a high of ₹1,820. This range helps investors understand the stock's price volatility and recent trading levels.
Does ERIS Lifesciences Ltd pay dividends?
Yes, ERIS Lifesciences Ltd has a dividend yield of 0.53%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd has a Return on Equity (ROE) of 11.45%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research ERIS Lifesciences Ltd on Tapetide?
On Tapetide, you can view ERIS Lifesciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Website eris.co.in
CEO Mr. Amit Indubhushan Bakshi
Employees 3,354
Listed 2017-06-29
Face Value ₹ 1
Issued Size 13,62,16,891

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List